세계의 경구 거담제 시장 조사 보고서 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2025-2033년)
Global Oral Expectorant Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2025 to 2033
상품코드:1820632
리서치사:Value Market Research
발행일:2025년 07월
페이지 정보:영문 143 Pages
라이선스 & 가격 (부가세 별도)
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
한글목차
세계의 경구 거담제 시장 예측은 대폭적인 성장을 예측하고 있으며, 시장 규모는 2033년까지 67억 8,000만 달러로, 2024년에 기록한 49억 달러에서 대폭 증가할 것으로 예측되고 있습니다. 이 확장은 2025-2033년 예상되는 3.68%의 경이적인 연평균 성장률(CAGR)을 반영합니다.
세계의 경구 거담제 시장은 기관지염, 만성 폐색성 폐질환(COPD), 민감성 등 호흡기 질환의 유병률 증가로 안정적인 성장이 예상됩니다. 거담제는 점액의 배출을 촉진하고 호흡 기능 및 환자의 편안함을 향상시킵니다. 향후 개발에서는 효능의 향상, 부작용의 경감, 천연 성분의 배합을 실현한 신규 제제가 주목됩니다.
또한 대기오염 및 흡연율 상승이 호흡기계의 건강 과제를 조장하고 있으며, 시장 수요를 확대하고 있습니다. 일반용 의약품(OTC)의 성장과 셀프 메디케이션의 동향은 소비자의 접근을 확대하고 있습니다. 서방형 요법 및 병용 요법을 포함한 약물 전달 기술의 발전으로 치료 성적이 향상되고 있습니다. 호흡기 케어의 진화에 따라 경구 거담제 시장도 혁신을 계속하고 안전하고 효과적이며 환자 친화적인 솔루션을 제공해 나갈 것입니다.
목차
제1장 서문
제2장 주요 요약
시장의 하이라이트
세계 시장 현황
제3장 경구 거담제 : 산업 분석
서문 : 시장 역학
시장 성장 촉진요인
시장 성장 억제요인
시장 기회
업계 동향
Porter's Five Forces 분석
시장 매력 분석
제4장 밸류체인 분석
밸류체인 분석
원재료 분석
원재료 리스트
원재료 제조업체 리스트
주요 원재료의 가격 동향
잠재적 구매자 목록
마케팅 채널
직접 마케팅
간접 마케팅
마케팅 채널 발전 동향
제5장 세계의 경구 거담제 시장 분석 : 약제 유형별
개요 : 약제 유형별
과거 및 예측 데이터 분석 : 약제 유형별
분비 촉진제
점액 용해제
제6장 세계의 경구 거담제 시장 분석 : 제형별
개요 : 제형별
과거 및 예측 데이터 분석 : 제형별
경구 고형제
경구 액체
흡입제
제7장 세계의 경구 거담제 시장 분석 : 약물별
개요 : 약물별
과거 및 예측 데이터 분석 : 약물별
처방약
시판약
제8장 세계의 경구 거담제 시장 분석 : 유통 채널별
개요 : 유통 채널별
과거 및 예측 데이터 분석 : 유통 채널별
병원 약국
소매점 및 약국
제9장 세계의 경구 거담제 시장 분석 : 지역별
지역별 전망
서문
북미의 매출 분석
개요, 분석 및 예측
북미 : 부문별
북미 국가별
미국
캐나다
멕시코
유럽의 매출 분석
개요, 분석 및 예측
유럽 : 부문별
유럽 국가별
영국
프랑스
독일
이탈리아
러시아
기타 유럽
아시아태평양의 매출 분석
개요, 분석 및 예측
아시아태평양 : 부문별
아시아태평양 국가별
중국
인도
일본
한국
호주
동남아시아
기타 아시아태평양
라틴아메리카의 매출 분석
개요, 분석 및 예측
라틴아메리카 : 부문별
라틴아메리카 국가별
브라질
아르헨티나
페루
칠레
기타 라틴아메리카
중동 및 아프리카의 매출 분석
개요, 분석 및 예측
중동 및 아프리카 부문별
중동 및 아프리카 국가별 일람
사우디아라비아
아랍에미리트(UAE)
이스라엘
남아프리카
기타 중동 및 아프리카
제10장 경구 거담제 기업 경쟁 구도
경구 거담제 시장의 경쟁
제휴, 협력 및 합의
합병 및 인수
신제품 발매
기타 개발
제11장 기업 프로파일
주요 기업의 시장 점유율 분석
시장 집중도
Abbott Laboratories
AstraZeneca
Cipla Inc.
Genexa Inc.
GlaxoSmithKline(GSK)Plc
Merck KGaA
Perrigo Company Plc
Reckitt Benckiser Group PLC
Sanofi
Sun Pharmaceutical Industries Ltd.
The Himalaya Drug Company
AJY
영문 목차
영문목차
The forecast for the global Oral Expectorant market predicts substantial growth, with market size projected to soar to USD 6.78 Billion by 2033, a significant increase from the USD 4.9 Billion recorded in 2024. This expansion reflects an impressive compound annual growth rate (CAGR) of 3.68% anticipated between 2025 and 2033.
The global oral expectorant market is set for steady growth driven by increasing prevalence of respiratory diseases such as bronchitis, chronic obstructive pulmonary disease (COPD), and common cold. Expectorants facilitate mucus clearance, improving respiratory function and patient comfort. Future developments will focus on novel formulations with enhanced efficacy, reduced side effects, and natural ingredient integration.
Additionally, rising air pollution and smoking rates are contributing to respiratory health challenges, expanding market demand. The growth of over-the-counter (OTC) products and self-medication trends is broadening consumer access. Advances in drug delivery technologies, including sustained-release and combination therapies, are improving treatment outcomes. As respiratory care evolves, the oral expectorant market will continue to innovate, delivering safe, effective, and patient-friendly solutions.
Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:
Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.
Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.
Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.
Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.
Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.
Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.
Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.
LIST OF SEGMENTS COVERED
This section of the Oral Expectorant market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Type
Secretion Enhancer
Mucolytics
By Dosage Form
Oral Solids
Oral Liquids
Inhalants
By Medication
Prescription Drugs
Over-The-Counter Drugs
By Distribution Channel
Hospital Pharmacies
Retail Store & Drug Store
List of Companies Profiled in the report
Abbott Laboratories, AstraZeneca, Cipla Inc., Genexa Inc., GlaxoSmithKline (GSK) plc, Merck KGaA, Perrigo Company plc, Reckitt Benckiser Group PLC, Sanofi, Sun Pharmaceutical Industries Ltd., The Himalaya Drug Company.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
3.7.2 Market Attractiveness Analysis By Dosage Form
3.7.3 Market Attractiveness Analysis By Medication
3.7.4 Market Attractiveness Analysis By Distribution Channel
3.7.5 Market Attractiveness Analysis By Regions
4. VALUE CHAIN ANALYSIS
4.1. Value Chain Analysis
4.2. Raw Material Analysis
4.2.1 List of Raw Materials
4.2.2 Raw Material Manufactures List
4.2.3 Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
4.4.1 Direct Marketing
4.4.2 Indirect Marketing
4.4.3 Marketing Channel Development Trend
5. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY DRUG TYPE
5.1. Overview By Drug Type
5.2. Historical and Forecast Data Analysis By Drug Type
5.3. Secretion Enhancer Historic and Forecast Sales By Regions
5.4. Mucolytics Historic and Forecast Sales By Regions
6. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY DOSAGE FORM
6.1. Overview By Dosage Form
6.2. Historical and Forecast Data Analysis By Dosage Form
6.3. Oral Solids Historic and Forecast Sales By Regions
6.4. Oral Liquids Historic and Forecast Sales By Regions
6.5. Inhalants Historic and Forecast Sales By Regions
7. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY MEDICATION
7.1. Overview By Medication
7.2. Historical and Forecast Data Analysis By Medication
7.3. Prescription Drugs Historic and Forecast Sales By Regions
7.4. Over-The-Counter Drugs Historic and Forecast Sales By Regions
8. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY DISTRIBUTION CHANNEL
8.1. Overview By Distribution Channel
8.2. Historical and Forecast Data Analysis By Distribution Channel
8.3. Hospital Pharmacies Historic and Forecast Sales By Regions
8.4. Retail Store & Drug Store Historic and Forecast Sales By Regions
9. GLOBAL ORAL EXPECTORANT MARKET ANALYSIS BY GEOGRAPHY
9.1. Regional Outlook
9.2. Introduction
9.3. North America Sales Analysis
9.3.1 Overview, Historic and Forecast Data Sales Analysis
9.3.2 North America By Segment Sales Analysis
9.3.3 North America By Country Sales Analysis
9.3.4 United States Sales Analysis
9.3.5 Canada Sales Analysis
9.3.6 Mexico Sales Analysis
9.4. Europe Sales Analysis
9.4.1 Overview, Historic and Forecast Data Sales Analysis
9.4.2 Europe By Segment Sales Analysis
9.4.3 Europe By Country Sales Analysis
9.4.4 United Kingdom Sales Analysis
9.4.5 France Sales Analysis
9.4.6 Germany Sales Analysis
9.4.7 Italy Sales Analysis
9.4.8 Russia Sales Analysis
9.4.9 Rest Of Europe Sales Analysis
9.5. Asia Pacific Sales Analysis
9.5.1 Overview, Historic and Forecast Data Sales Analysis
9.5.2 Asia Pacific By Segment Sales Analysis
9.5.3 Asia Pacific By Country Sales Analysis
9.5.4 China Sales Analysis
9.5.5 India Sales Analysis
9.5.6 Japan Sales Analysis
9.5.7 South Korea Sales Analysis
9.5.8 Australia Sales Analysis
9.5.9 South East Asia Sales Analysis
9.5.10 Rest Of Asia Pacific Sales Analysis
9.6. Latin America Sales Analysis
9.6.1 Overview, Historic and Forecast Data Sales Analysis
9.6.2 Latin America By Segment Sales Analysis
9.6.3 Latin America By Country Sales Analysis
9.6.4 Brazil Sales Analysis
9.6.5 Argentina Sales Analysis
9.6.6 Peru Sales Analysis
9.6.7 Chile Sales Analysis
9.6.8 Rest of Latin America Sales Analysis
9.7. Middle East & Africa Sales Analysis
9.7.1 Overview, Historic and Forecast Data Sales Analysis
9.7.2 Middle East & Africa By Segment Sales Analysis
9.7.3 Middle East & Africa By Country Sales Analysis
9.7.4 Saudi Arabia Sales Analysis
9.7.5 UAE Sales Analysis
9.7.6 Israel Sales Analysis
9.7.7 South Africa Sales Analysis
9.7.8 Rest Of Middle East And Africa Sales Analysis
10. COMPETITIVE LANDSCAPE OF THE ORAL EXPECTORANT COMPANIES
10.1. Oral Expectorant Market Competition
10.2. Partnership/Collaboration/Agreement
10.3. Merger And Acquisitions
10.4. New Product Launch
10.5. Other Developments
11. COMPANY PROFILES OF ORAL EXPECTORANT INDUSTRY
11.1. Top Companies Market Share Analysis
11.2. Market Concentration Rate
11.3. Abbott Laboratories
11.3.1 Company Overview
11.3.2 Company Revenue
11.3.3 Products
11.3.4 Recent Developments
11.4. AstraZeneca
11.4.1 Company Overview
11.4.2 Company Revenue
11.4.3 Products
11.4.4 Recent Developments
11.5. Cipla Inc.
11.5.1 Company Overview
11.5.2 Company Revenue
11.5.3 Products
11.5.4 Recent Developments
11.6. Genexa Inc.
11.6.1 Company Overview
11.6.2 Company Revenue
11.6.3 Products
11.6.4 Recent Developments
11.7. GlaxoSmithKline (GSK) Plc
11.7.1 Company Overview
11.7.2 Company Revenue
11.7.3 Products
11.7.4 Recent Developments
11.8. Merck KGaA
11.8.1 Company Overview
11.8.2 Company Revenue
11.8.3 Products
11.8.4 Recent Developments
11.9. Perrigo Company Plc
11.9.1 Company Overview
11.9.2 Company Revenue
11.9.3 Products
11.9.4 Recent Developments
11.10. Reckitt Benckiser Group PLC
11.10.1 Company Overview
11.10.2 Company Revenue
11.10.3 Products
11.10.4 Recent Developments
11.11. Sanofi
11.11.1 Company Overview
11.11.2 Company Revenue
11.11.3 Products
11.11.4 Recent Developments
11.12. Sun Pharmaceutical Industries Ltd.
11.12.1 Company Overview
11.12.2 Company Revenue
11.12.3 Products
11.12.4 Recent Developments
11.13. The Himalaya Drug Company
11.13.1 Company Overview
11.13.2 Company Revenue
11.13.3 Products
11.13.4 Recent Developments
Note - In company profiling, financial details and recent developments are subject to availability or might not be covered in the case of privcompanies
